Protara Therapeutics Stock Market Value
| TARA Stock | USD 4.50 0.02 0.44% |
| Symbol | Protara |
Protara Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Protara Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Protara Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Protara Therapeutics.
| 01/01/2025 |
| 01/31/2025 |
If you would invest 0.00 in Protara Therapeutics on January 1, 2025 and sell it all today you would earn a total of 0.00 from holding Protara Therapeutics or generate 0.0% return on investment in Protara Therapeutics over 30 days. Protara Therapeutics is related to or competes with Monopar Therapeutics, Surrozen, Ikena Oncology, Xilio Development, Scholar Rock, Lyra Therapeutics, and Trevi Therapeutics. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transfo... More
Protara Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Protara Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Protara Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.29 | |||
| Information Ratio | 0.1485 | |||
| Maximum Drawdown | 78.24 | |||
| Value At Risk | (7.16) | |||
| Potential Upside | 13.0 |
Protara Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protara Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Protara Therapeutics' standard deviation. In reality, there are many statistical measures that can use Protara Therapeutics historical prices to predict the future Protara Therapeutics' volatility.| Risk Adjusted Performance | 0.1411 | |||
| Jensen Alpha | 1.67 | |||
| Total Risk Alpha | 0.5217 | |||
| Sortino Ratio | 0.2969 | |||
| Treynor Ratio | (17.41) |
Protara Therapeutics Backtested Returns
Protara Therapeutics is dangerous given 3 months investment horizon. Protara Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.13, which implies the firm had a 0.13 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.41% are justified by taking the suggested risk. Use Protara Therapeutics Semi Deviation of 3.99, risk adjusted performance of 0.1411, and Coefficient Of Variation of 633.29 to evaluate company specific risk that cannot be diversified away. Protara Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of -0.0954, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Protara Therapeutics are expected to decrease at a much lower rate. During the bear market, Protara Therapeutics is likely to outperform the market. Use Protara Therapeutics expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to analyze future returns on Protara Therapeutics.
Auto-correlation | 0.64 |
Good predictability
Protara Therapeutics has good predictability. Overlapping area represents the amount of predictability between Protara Therapeutics time series from 1st of January 2025 to 16th of January 2025 and 16th of January 2025 to 31st of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Protara Therapeutics price movement. The serial correlation of 0.64 indicates that roughly 64.0% of current Protara Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.64 | |
| Spearman Rank Test | 0.87 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Protara Therapeutics lagged returns against current returns
Autocorrelation, which is Protara Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Protara Therapeutics' stock expected returns. We can calculate the autocorrelation of Protara Therapeutics returns to help us make a trade decision. For example, suppose you find that Protara Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Protara Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Protara Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Protara Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Protara Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Protara Therapeutics Lagged Returns
When evaluating Protara Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Protara Therapeutics stock have on its future price. Protara Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Protara Therapeutics autocorrelation shows the relationship between Protara Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Protara Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out Protara Therapeutics Correlation, Protara Therapeutics Volatility and Protara Therapeutics Alpha and Beta module to complement your research on Protara Therapeutics. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Protara Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.